Asprosin Infusion Modulates Central Circuits to Rescue Selective Serotonin Reuptake Inhibitor-Induced Male Dysfunction

Asprosin injected directly into rat brains reversed paroxetine-induced erectile dysfunction, sperm loss, and testicular damage across all 5 endpoints measured

Journal: Reproduction (Cambridge, England) | Published: 2026-04-05 | Type: Journal Article | PMID: 41873723 Authors: Tan F, Oz ZD, Zorlu G, et al. (Firat University, Yeditepe University, Dokuz Eylül University, and others — all Turkish academic institutions) Funding/COI: The Scientific and Technological Research Council of Turkey; no COI listed

Summary

SSRI antidepressants are among the most prescribed drugs on earth and sexual dysfunction is one of their most common side effects — a problem with no good pharmacological fix. This rat study tests whether asprosin, a hunger-signaling protein that crosses the blood-brain barrier and activates appetite-promoting neurons, can rescue the erectile, ejaculatory, sperm, and testicular damage caused by paroxetine. In 60 male Sprague-Dawley rats, it largely did. Whether any of that translates to humans depends on solving a delivery problem that would give most neurologists a headache.

Claims

• Paroxetine (20 mg/kg/day oral) reduced sperm concentration versus controls; asprosin (500 ng/kg/day intracerebroventricular) increased sperm concentration above both control and paroxetine groups
• Total sperm motility fell in the paroxetine group and was restored to baseline by asprosin co-treatment
• Paroxetine caused histological testicular damage — interstitial edema, vascular congestion, seminiferous tubule basement membrane detachment — which asprosin ameliorated
• Asprosin enhanced erectile responses, facilitated ejaculation, and increased sexual motivation on behavioral assessments
• Asprosin decreased prolactin and increased oxytocin levels
• Kiss1 and Rfrp-3 mRNA (hypothalamic reproductive regulators) were not altered by paroxetine alone; paroxetine counteracted asprosin-induced elevations of both in the arcuate nucleus and dorsomedial hypothalamus
• All findings statistically significant at p < 0.05

Study Quality

This is a controlled animal experiment — 60 rats, 5 groups of 12, with a sham arm and appropriate comparators (paroxetine alone, asprosin alone, combination). The multi-domain outcome approach is a genuine strength: behavioral endpoints, hormone assays, sperm parameters, and tissue histology together tell a more complete story than any single measure. The mechanistic framing — asprosin acting on AgRP neurons to modulate the hypothalamic-pituitary-gonadal axis — is biologically plausible and the hypothalamic gene expression data attempts to ground it.

The central methodological flaw is the delivery route. Asprosin was administered via intracerebroventricular infusion — a cannula surgically implanted into the brain. This is a standard preclinical technique for testing whether a compound works centrally, but it has essentially zero clinical relevance. Nobody is drilling into human skulls to treat SSRI side effects. The paper gestures at asprosin's ability to cross the blood-brain barrier as a future avenue for systemic delivery, but that work is not done here. The rat paroxetine dose (20 mg/kg/day) also far exceeds human therapeutic dosing when adjusted for body surface area, raising questions about whether the dysfunction model reflects typical clinical exposure.

Red Flags

• Animal study, n=12 per group: rodent sexual behavior and hormonal axes differ substantially from human physiology; findings frequently fail to replicate across species
• Intracerebroventricular delivery: no clinically viable route is tested or demonstrated; the paper's central finding is contingent on a delivery method that does not exist outside a surgical suite
• No pharmacokinetic data: asprosin half-life, receptor binding, off-target effects in this model are not characterized
• Paroxetine dose: 20 mg/kg/day in rats is a suprapharmacological exposure relative to human dosing; the dysfunction model may be an artifact of overdose rather than therapeutic-level SSRI use
• No COI declaration: the absence of a conflict of interest statement rather than an affirmative "none declared" is a reporting gap, not necessarily a red flag, but worth noting
• Sperm concentration above control: asprosin-alone animals showed sperm concentration exceeding controls — this unexplained hyperresponse is not discussed and raises questions about physiological plausibility

Strengths

• Multi-domain outcome battery (behavior, hormones, sperm, histology) provides mechanistic breadth
• Randomized design with appropriate control and sham arms
• Hypothalamic gene expression data (Kiss1, Rfrp-3) attempts mechanistic grounding rather than just reporting endpoints
• Government-funded research with no reported industry involvement
• Histological confirmation of testicular damage and repair adds objectivity to the behavioral findings

Verdict

This paper establishes proof-of-concept that centrally delivered asprosin reverses SSRI-induced male reproductive dysfunction in rats — a result interesting enough to justify further preclinical work. The mechanistic hypothesis (asprosin → AgRP neurons → HPG axis → restored reproductive function) is coherent and worth pursuing. But the gap between "works when injected into a rat's brain" and "clinically actionable treatment for SSRI side effects" is enormous, and this paper does nothing to close it. Read it as hypothesis generation, not as evidence for a treatment. The intracerebroventricular delivery route alone should prevent anyone from overstating what these findings mean.